As a pioneering innovator in the global IVD industry, Rendu Bio has been a regular exhibitor at Medlab Middle East for many years. In 2025, we return to Dubai with our full range of IVD products, showcasing a more mature brand image and advanced technological capabilities. With extensive exhibition experience, we understand our customers' needs better than ever. This year, our booth design, product demonstrations, and interactive sessions have drawn a great deal of interest from industry peers.
Rendu’s molecular diagnostic solutions have garnered strong interest from customers across the Middle East, Europe, and North America. In addition to our exclusive product portfolio, our newly launched Digital SAT early cancer screening technology took centre stage. Leveraging our proprietary RNA isothermal amplification platform, this breakthrough technology accurately detects multiple precancerous biomarkers, attracting a steady stream of inquiries. Many distributors have expressed that Rendu’s innovations align well with regional disease profiles, presenting significant collaboration opportunities in the future.
Medlab 2025 is not just a platform for brand exposure—it marks a key milestone in Rendu’s globalization strategy. We have witnessed the growing demand for precision medicine in emerging markets and received strong recognition for our product innovations. Moving forward, Rendu will continue to enhance R&D investments, accelerate localized service expansion, and work hand in hand with global partners to advance diagnostic accessibility, ensuring more patients benefit from the vision of "early detection and early treatment."
Phone · +86 021-50720200 Address · Building 15B, No. 528 Ruiqing Road, East District, Zhangjiang High tech Park, Shanghai Email · hr@rdbio.com（Domestic Affairs） sales@rdbio.com（International Trade）
